ColoHealth
Colorectal Cancer Screening
ApprovedActive
Key Facts
About New Day Diagnostics
New Day Diagnostics is an emerging, vertically integrated diagnostics company with a dual-pronged business model. It commercially offers ColoHealth, a blood-based test for colorectal cancer (CRC) screening with a validated 99.7% Negative Predictive Value (NPV), and provides diagnostic Contract Research Organization (CRO) services to other developers. The company is pursuing aggressive growth through strategic mergers, like EDP Biotech, and partnerships to expand its commercial footprint and pipeline into other cancers and infectious diseases. Its operations are supported by a CLIA-certified, ISO 13485-accredited laboratory, underpinning both its product commercialization and service offerings.
View full company profileTherapeutic Areas
Other Colorectal Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Shield (ECLIPSE Study) | Guardant Health | FDA Approved |
| Urine cfDNA Test for Colon Cancer Screening | JBS Science | Development |
| iFOB | Pangea Laboratory | Commercial |
| CRC Screening Program | Polymedco | Commercial |
| SimpleScreen CRC | Freenome | Commercial (as LDT) |
| ColoScape™ / QuantiDNA™ | DiaCarta | Commercial |
| ColoSense | Geneoscopy | Approved |
| At-Home Colorectal Cancer Screening | SNT Biotech | Commercial |
| FIT System & Assay Development | Sentinel Diagnostics | Commercial |
| Next-Generation Cologuard® | Exact Sciences | Development |
| ColoAlert® | Mainz Biomed | Pivotal Trial |